Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

Group 1: Company Performance and Financials - IQVIA reported fourth-quarter revenue of $4.36 billion, exceeding the consensus estimate of $4.08 billion [3] - The company achieved near double-digit revenue and EPS growth in 2025, with strong performance across all segments [3] - CEO Ari Bousbib highlighted that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth [3] Group 2: Analyst Ratings and Price Target - Morgan Stanley lowered its price target on IQVIA Holdings Inc. to $240 from $265 but maintained an Overweight rating [1][5] - The adjustment in price target followed the company's quarterly results [1] Group 3: Strategic Collaborations - IQVIA and the Duke Clinical Research Institute announced a collaboration to advance clinical research in obesity and related cardiometabolic trials [2] - The partnership aims to set a new standard for collaboration between life science service companies and academic research organizations, focusing on improving trial efficiency [2]